Insider Trading July 8, 2026 04:11 PM

Simulations Plus CRO John DiBella Executes $18,360 Stock Sale Amid Acquisition Talks and Earnings Preview

Chief Revenue Officer's transaction follows a definitive agreement for an all-cash acquisition and coincides with upcoming quarterly results.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SLP

John Anthony DiBella II, serving as Chief Revenue Officer for Simulations Plus, Inc. (NASDAQ: SLP), disposed of 1,000 shares of the company's common stock on July 6, 2026. The transaction totaled $18,360 and was executed through multiple sales priced between $18.34 and $18.39 per share. The sale was conducted automatically under a Rule 10b5-1 trading plan previously established by DiBella. Following the transaction, DiBella retains a direct holding of 86,140 shares in Simulations Plus. The sale occurs as the stock trades near $18.27, reflecting a significant 60% increase from its 52-week low of $11.09. This activity precedes the company's earnings report scheduled for July 9. Concurrently, Simulations Plus has agreed to be acquired by affiliates of Altaris, LLC in an all-cash deal valued at approximately $375 million. Under the terms, shareholders will receive $18.50 per share, representing a 26% premium over the 60-day volume-weighted average price. William Blair downgraded the stock from Outperform to Market Perform following the acquisition announcement. Additionally, the company is expanding its collaboration with Nvidia by integrating the Nvidia BioNeMo Agent Toolkit into its AI platform for drug development.

Simulations Plus CRO John DiBella Executes $18,360 Stock Sale Amid Acquisition Talks and Earnings Preview
SLP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • John Anthony DiBella II, Chief Revenue Officer of Simulations Plus, sold 1,000 shares totaling $18,360 via a Rule 10b5-1 plan, leaving him with 86,140 shares.
  • Simulations Plus agreed to an all-cash acquisition by Altaris, LLC affiliates for $375 million, offering shareholders $18.50 per share, a 26% premium.
  • The company is expanding its collaboration with Nvidia by integrating the BioNeMo Agent Toolkit into its AI platform to enhance GPU-accelerated drug development workflows.

John Anthony DiBella II, the Chief Revenue Officer at Simulations Plus, Inc. (NASDAQ: SLP), executed a sale of 1,000 shares of the company's common stock on July 6, 2026. The total value of this transaction was $18,360. The shares were sold through multiple transactions at prices ranging from $18.34 to $18.39 per share. This sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. DiBella.

Following the transaction, Mr. DiBella directly holds 86,140 shares of Simulations Plus common stock. The insider sale comes as the stock trades near $18.27, showing strong momentum with gains of over 60% from its 52-week low of $11.09. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company's Fair Value estimated significantly higher. The timing is notable as Simulations Plus is set to report earnings on July 9, just days away. InvestingPro subscribers have access to 12 additional exclusive tips about SLP, including detailed analysis of the company's financial health and growth prospects.

In other recent news, Simulations Plus Inc. has entered into a definitive agreement to be acquired by affiliates of Altaris, LLC in an all-cash transaction valued at approximately $375 million. Shareholders of Simulations Plus will receive $18.50 per share, marking a 26% premium to the company's 60-day volume-weighted average price. Following this announcement, William Blair downgraded the stock from Outperform to Market Perform. In parallel, Simulations Plus is expanding its collaboration with Nvidia, integrating the Nvidia BioNeMo Agent Toolkit into its AI platform for drug development. This partnership is expected to enhance their GPU-accelerated simulation and AI-assisted modeling workflows.

Additionally, Citizens has reiterated a Market Outperform rating on NRC Health stock, maintaining a price target of $23.00. This follows a review of recent financial results and investor focus areas at the firm's Healthcare Services Forum. These developments reflect ongoing strategic movements and partnerships within the healthcare and technology sectors.

Risks

  • William Blair downgraded the stock from Outperform to Market Perform following the acquisition announcement, indicating potential market sentiment shifts.
  • The stock's 60% gain from its 52-week low may introduce volatility as the company approaches its earnings report on July 9.

More from Insider Trading

Meta Platforms COO Javier Olivan Executes $3.15 Million Share Sale Under Pre-Arranged Trading Plan Jul 8, 2026 BillionToOne CEO Atay Oguzhan Executes $4.7M Share Sale Under Pre-Arranged Plan Jul 8, 2026 Snowflake Director Michael L Speiser Offloads $12.2M in Stock Under Pre-Arranged Plan Jul 8, 2026 Snowflake Director Michael Speiser Offloads $216K in Shares Through Pre-Arranged Plan Jul 8, 2026 Snowflake Director Michael L Speiser Disposes of $649,925 in Shares Under Pre-Arranged Plan Jul 8, 2026